These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31266707)

  • 1. Use of Bevacizumab for Elderly Patients With Stage IV Colon Cancer: Analysis of SEER-Medicare Data.
    Raab GT; Lin A; Hillyer GC; Keller D; O'Neil DS; Accordino MK; Buono DL; Hur C; Kiran RP; Wright JD; Hershman DL; Neugut AI
    Clin Colorectal Cancer; 2019 Sep; 18(3):e294-e299. PubMed ID: 31266707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data.
    Neugut AI; Lin A; Raab GT; Hillyer GC; Keller D; O'Neil DS; Accordino MK; Kiran RP; Wright J; Hershman DL
    Clin Colorectal Cancer; 2019 Jun; 18(2):133-140. PubMed ID: 30878317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.
    Panchal JM; Lairson DR; Chan W; Du XL
    Clin Colorectal Cancer; 2013 Jun; 12(2):113-21. PubMed ID: 23137529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer.
    Bikov KA; Mullins CD; Hung A; Seal B; Onukwugha E; Hanna N
    Oncologist; 2016 Jun; 21(6):676-83. PubMed ID: 27125751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.
    Zuckerman IH; Rapp T; Onukwugha E; Davidoff A; Choti MA; Gardner J; Seal B; Mullins CD
    J Am Geriatr Soc; 2009 Aug; 57(8):1403-10. PubMed ID: 19563521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.
    Sanoff HK; Carpenter WR; Stürmer T; Goldberg RM; Martin CF; Fine JP; McCleary NJ; Meyerhardt JA; Niland J; Kahn KL; Schymura MJ; Schrag D
    J Clin Oncol; 2012 Jul; 30(21):2624-34. PubMed ID: 22665536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.
    Hsiao FY; Mullins CD; Onukwugha E; Pandya N; Hanna N
    J Am Geriatr Soc; 2011 Sep; 59(9):1717-23. PubMed ID: 21831168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
    Mullins CD; Hsiao FY; Onukwugha E; Pandya NB; Hanna N
    Cancer; 2012 Jun; 118(12):3173-81. PubMed ID: 22020739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Medicare Claims-based Proxy Measures of Poor Function and Associations With Treatment Receipt and Mortality in Older Colon Cancer Patients.
    Mayer SE; Tan HJ; Peacock Hinton S; Sanoff HK; Stürmer T; Hester LL; Faurot KR; Jonsson Funk M; Lund JL
    Med Care; 2019 Apr; 57(4):286-294. PubMed ID: 30789540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period: A SEER-Medicare Analysis.
    Jiao X; Hay JW; Sadeghi S; Barzi A
    Am J Clin Oncol; 2020 Jun; 43(6):428-434. PubMed ID: 32187027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
    Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
    Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
    Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data.
    Weiss JM; Schumacher J; Allen GO; Neuman H; Lange EO; Loconte NK; Greenberg CC; Smith MA
    Ann Surg Oncol; 2014 Jun; 21(6):1781-91. PubMed ID: 24643898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential Therapies and the Cost-Effectiveness of Treating Metastatic Colon Cancer Patients.
    Woldemichael A; Onukwugha E; Seal B; Hanna N; Mullins CD
    J Manag Care Spec Pharm; 2016 Jun; 22(6):628-39. PubMed ID: 27231791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer.
    Obeidat NA; Pradel FG; Zuckerman IH; DeLisle S; Mullins CD
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):343-54. PubMed ID: 20129255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of second-line chemotherapy/biologics among elderly metastatic colon cancer patients.
    Zheng Z; Onukwugha E; Hanna N; Bikov K; Seal B; Mullins CD
    Adv Ther; 2014 Jul; 31(7):724-34. PubMed ID: 25022528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
    JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
    Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
    Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
    Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of chemotherapy in older patients with stage II and III colon cancer: Variation by age and era of diagnosis.
    Green SL; Dawe DE; Nugent Z; Cheung WY; Czaykowski PM
    J Geriatr Oncol; 2019 Jan; 10(1):132-137. PubMed ID: 30104156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.